Iovance Biotherapeutics: UBS raises target price to $8 from $7
IOVA•UBS raised its price target for Iovance Biotherapeutics to $8 from $7.
Related News
Lobo reports overseas order wins for new electric vehicle models
LOBO•
KLP 2006-N3 Family Trust reports sale of $11.41 million in Hyatt Hotels common shares
H•
LTC tops 2026 mid-point shop acquisition guidance with $62 million transaction, welcomes Grace Management
LTC•
Onterris says proposed EPA methane rule could expand emissions monitoring market
ONT•
Marriott publishes Q3 2026 earnings call transcript
MAR•